Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

Summary

This is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day residential phase wherein participants are stabilized on sublingual buprenorphine/naloxone, followed by a 3-week outpatient phase wherein participants are maintained on sublingual buprenorphine/naloxone and transitioned to extended-release buprenorphine).

Timeline

Start

2022-03-30

Primary completion

2026-08

Completion

2026-08

Drugs

Indications